

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Brii Biosciences Limited**  
**騰盛博药生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2137)**

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING  
HELD ON SEPTEMBER 1, 2023**

References are made to the notice of extraordinary general meeting (the “**Notice**”) of Brii Biosciences Limited (the “**Company**”) dated August 4, 2023, the circular of the Company (the “**Circular**”) dated August 4, 2023 and the announcement of the Company dated August 20, 2023, in relation to, among others, postponement of the extraordinary general meeting. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

**POLL RESULTS OF THE EGM**

The Board is pleased to announce that at the EGM held on Thursday, August 31, 2023, at 9:00 p.m. (The Eastern Time)/Friday, September 1, 2023 at 9:00 a.m. (Hong Kong Time), all the proposed resolutions as set out in the Notice were taken by way of poll.

The poll results in respect of the resolutions proposed at the EGM are as follows:

Ordinary Resolutions		Number of Votes Cast (Approximate percentage of number of votes cast (%))	
		For	Against
1.	To approve the adoption of the 2023 Share Option Scheme (as defined in the Circular) and the termination of the Existing Share Option Scheme (as defined in the Circular) subject to and conditional upon the 2023 Share Option Scheme becoming unconditional and effective.	211,795,281 (93.72%)	14,199,425 (6.28%)
2.	To approve the adoption of the 2023 Share Award Scheme (as defined in the Circular) and the termination of the Existing Share Award Scheme (as defined in the Circular) subject to and conditional upon the 2023 Share Award Scheme becoming unconditional and effective.	211,795,281 (93.72%)	14,199,425 (6.28%)

Ordinary Resolutions		Number of Votes Cast (Approximate percentage of number of votes cast (%))	
		For	Against
3.	Conditional upon the above ordinary resolutions no. 1 and 2 being duly passed, to approve the adoption of the Scheme Mandate Limit (as defined in the Circular).	211,795,281 (93.72%)	14,199,425 (6.28%)
4.	Conditional upon the above ordinary resolutions no. 1 and 2 being duly passed, to approve the adoption of the Service Provider Sublimit (as defined in the Circular).	211,795,281 (93.72%)	14,199,425 (6.28%)

*Notes:*

- (a) The full text of the above resolutions appears in the Notice.
- (b) As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 4 at the EGM, such resolutions were duly passed as ordinary resolutions.
- (c) As at the date of the EGM, the total number of Shares in issue was 728,130,784 Shares.
- (d) The total number of Shares entitling the holder to attend and vote on the resolutions at the EGM was 728,130,784 Shares.
- (e) There were no Shares entitling the holder to attend and abstain from voting in favour of the resolutions at the EGM as set out in Rule 13.40 of the Listing Rules.
- (f) No Shareholder was required under the Listing Rules to abstain from voting on the resolutions at the EGM.
- (g) None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the EGM.
- (h) The Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM.
- (i) Dr. Zhi Hong, Dr. Ankang Li, Mr. Robert Taylor Nelsen, Dr. Martin J Murphy Jr, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton, and Dr. Taiyin Yang attended the EGM by electronic means.

By order of the Board  
**Brii Biosciences Limited**  
**Dr. Zhi Hong**  
*Chairman*

Hong Kong, September 1, 2023

*As at the date of this announcement, the Board comprises Dr. Zhi Hong and Dr. Ankang Li as executive Directors; Mr. Robert Taylor Nelsen as non-executive Director; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton and Dr. Taiyin Yang as independent non-executive Directors.*